CEO Executive AssistantPediatric drug development sits at the intersection of scientific complexity, regulatory specificity, and profound ethical responsibility. Children are not small adults. Their pharmacokinetics differ significantly from adults, their developmental stages affect both drug behavior and safety outcomes, and the ethical framework for enrolling them in clinical trials carries obligations that require exceptional organizational discipline. For pharma CEOs managing pediatric drug development operations, this guide addresses the strategic and operational frameworks needed to build a compliant, scientifically rigorous, and commercially viable pediatric program.
The Regulatory and Scientific Foundation
Before addressing operations, CEOs must understand the regulatory architecture that shapes pediatric drug development. Two key U.S. legislative frameworks define the landscape: the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA). Together, these statutes create both requirements and incentives that form the operational backbone of any pediatric program.
PREA requires that sponsors submit pediatric study plans for certain drugs and biologics, mandating assessment of safety and effectiveness across relevant pediatric age groups when the drug is being developed for a condition that also occurs in children. The FDA issues Written Requests under BPCA when it determines that a drug could benefit pediatric patients, and companies that complete studies in response to Written Requests are eligible for six months of additional market exclusivity, a significant commercial incentive.
Operationally, CEOs need to ensure their regulatory affairs teams are current on FDA pediatric guidance, that pediatric development planning is integrated into the overall program development strategy rather than treated as a late-stage add-on, and that internal governance processes exist to review Pediatric Study Plans before submission. Surprises in the regulatory review process are costly; proactive FDA engagement through the Pediatric Review Committee process reduces risk considerably.
Building Pediatric Development Operations
Running pediatric clinical trials requires organizational capabilities that differ meaningfully from adult drug development. Site selection, patient recruitment, data collection, and safety monitoring all require pediatric-specific expertise and infrastructure.
Site selection for pediatric trials must prioritize institutions with established pediatric research infrastructure, including dedicated clinical trial units, experienced pediatric pharmacologists, and the regulatory and IRB frameworks to review and approve pediatric protocols efficiently. Academic medical centers with pediatric departments, children’s hospitals with research programs, and global pediatric networks through organizations like the Pediatric Trials Network and the European Paediatric Formulation Initiative are key ecosystem partners. Building relationships with these institutions before you need them for a specific trial is an operational investment that accelerates timelines.
Patient recruitment in pediatric trials is consistently among the most significant operational challenges. The eligible patient population for any given pediatric study is smaller than in adult trials, and families face significant logistical and emotional barriers to participation. CEOs must ensure their clinical operations teams develop recruitment strategies that account for family decision-making dynamics, geographic access challenges, and the burden of trial participation on children and their caregivers. Decentralized trial elements, including home nursing visits, remote monitoring, and telemedicine follow-up, can meaningfully reduce participation burden and improve recruitment and retention rates.
Protocol design for pediatric studies requires particular attention to age-appropriate endpoints, assessment tools validated in pediatric populations, and data collection procedures that minimize patient burden. Regulatory affairs and clinical development teams must work closely together during protocol development to ensure that the study design will generate data sufficient for regulatory submission while remaining feasible in the real-world clinical environment.
Pediatric Dosing and Formulation Development
One of the most operationally distinctive aspects of pediatric drug development is formulation. Children across different age groups, from neonates to adolescents, have profoundly different dosing needs and formulation requirements. A tablet appropriate for a twelve-year-old is simply not acceptable for a two-year-old. Building dosing development operations that can address the full pediatric age spectrum requires specialized pharmaceutical sciences capabilities.
The EMA and FDA have issued guidance on developmentally appropriate formulations that CEOs should require their development teams to follow. These guidelines address palatability, dosage form appropriateness by age, and the excipient safety considerations unique to pediatric populations (because some excipients safe for adults are not safe for neonates or infants). Running palatability studies, developing flexible dose formulations that allow weight-based dosing, and building age-appropriate packaging and administration tools all require dedicated pharmaceutical sciences resources and operational timelines that must be built into your overall program plan.
Pharmacokinetic modeling and simulation have become essential tools in pediatric dosing development. Rather than conducting extensive empirical dosing studies in each age group separately, sponsors increasingly use physiologically-based pharmacokinetic models populated with pediatric physiological data to predict dosing requirements across age groups, with targeted clinical PK studies to validate model predictions. CEOs should ensure their quantitative pharmacology capabilities include pediatric PBPK expertise and that these tools are integrated early in development planning. See pharma business checklist for a broader operational readiness framework across your development programs.
FDA Pediatric Incentives and Exclusivity Operations
Six months of additional market exclusivity through BPCA is a commercially significant incentive that requires careful operational management. To qualify, a sponsor must receive a Written Request from FDA, complete the requested studies, and submit a report that meets FDA requirements. Each of these steps requires specific operational capabilities and timelines.
Managing the Written Request process begins with proactive engagement with the FDA Pediatric Review Committee. CEOs should work with regulatory affairs to submit a Proposed Pediatric Study Request before receiving a Written Request, allowing early alignment with FDA on the studies that will be needed. Disagreements about the scope of required pediatric studies can be resolved through the dispute resolution process, but this adds time and resource. Early alignment is always preferable.
Exclusivity tracking requires operational infrastructure to monitor and communicate the pediatric exclusivity window across commercial, legal, payer, and manufacturing functions. The six-month window provides a finite but valuable commercial opportunity that must be maximized through coordinated operational planning. Commercial teams need to build their pricing and contracting strategies around the exclusivity period; manufacturing must plan inventory to support peak demand during this window; and legal must monitor for potential challenges.
Orphan Drug Designation, available for drugs targeting rare diseases that may also affect pediatric populations, interacts with pediatric exclusivity in complex ways that require regulatory expertise to navigate. CEOs managing programs that may qualify for both Orphan Drug and pediatric incentives should ensure their regulatory and legal teams have mapped out all potential exclusivity scenarios and their commercial implications.
Caregiver Engagement Operations
In pediatric drug development and commercial programs, the primary decision-maker is often not the patient. Parents and caregivers make treatment decisions for children, manage drug administration, monitor for adverse effects, and interface with the healthcare system on behalf of their children. Building operational infrastructure that effectively engages caregivers is therefore central to both clinical trial success and commercial performance.
Patient and family engagement in clinical trial design is a research ethics requirement and a practical necessity. Caregivers can identify protocol design elements that create unacceptable burden, suggest outcome measures that reflect what matters most to families, and help develop recruitment materials and consent processes that are genuinely informative and accessible. Building a Patient Family Advisory Board that is integrated into your pediatric development operations brings these benefits systematically rather than through ad hoc consultation.
Commercial patient support programs for pediatric products must serve both the child patient and the caregiver. Medication adherence in pediatric populations is mediated almost entirely through caregiver behavior, meaning that patient support programs must address caregiver knowledge, skills, and barriers rather than just providing information to the patient. Operational design of these programs should include caregiver needs assessment research, program testing with caregiver panels, and ongoing monitoring of caregiver satisfaction and program effectiveness.
School accommodation support is an often-overlooked element of patient support for pediatric chronic disease programs. Children on long-term medications may require school health plan accommodations, storage and administration support during the school day, and documentation for educational services. Building school support resources into your patient support program infrastructure demonstrates a genuine understanding of the pediatric patient experience and differentiates your organization from competitors who have not thought through these operational details.
Safety Monitoring and Pharmacovigilance for Pediatric Products
Safety monitoring for pediatric drug programs requires heightened vigilance and specialized operational capabilities. Children’s developing physiology creates the potential for adverse effects that do not occur in adults, and long-term developmental outcomes may not become apparent until years after drug exposure. The ethical and regulatory obligations for pediatric pharmacovigilance are therefore more demanding than for adult products.
Risk Management Plans for pediatric products typically include pediatric-specific risk minimization measures, including age-appropriate prescribing guidance, caregiver education on warning signs, and in some cases, restricted distribution through Risk Evaluation and Mitigation Strategies programs. CEOs must ensure that their pharmacovigilance and regulatory teams have the expertise to design and implement these risk management systems and that post-marketing safety commitments to FDA are tracked and fulfilled.
Pediatric registries and long-term follow-up studies are increasingly expected for novel therapies, particularly those that are administered during developmentally sensitive periods or that target rare pediatric conditions with limited prior safety databases. Building registry operations requires dedicated epidemiology and data management resources, IRB oversight frameworks, and patient engagement strategies that sustain participation over multi-year follow-up periods.
According to the FDA’s pediatric program annual reports, the combination of BPCA and PREA has resulted in thousands of labeling changes providing pediatric prescribing information that was previously absent, demonstrating the system-wide impact of well-designed regulatory incentives on pediatric drug development investment.
Commercial Operations for Pediatric Products
Commercializing pediatric products requires field force configurations and customer engagement strategies optimized for the pediatric prescriber universe. Depending on the therapeutic area, your prescriber base may include pediatricians, pediatric subspecialists (pediatric neurologists, pediatric rheumatologists, pediatric oncologists), neonatologists, and hospital-based pharmacists who manage pediatric formularies.
Pediatric hospital formulary processes are particularly important for drugs administered in inpatient settings or specialty clinics. Hospital pharmacies and Pharmacy and Therapeutics committees evaluate pediatric products based on clinical evidence, safety profiles, and economic considerations. Building relationships with pediatric clinical pharmacists and hospital pharmacy leadership is an essential commercial operations activity that requires dedicated account management resources.
Medical affairs engagement with pediatric key opinion leaders involves both academic researchers at children’s hospitals and community pediatric subspecialists who see high patient volumes. Medical science liaisons serving the pediatric market need specific training on pediatric pharmacology, developmental considerations, and the evidence base for your products in pediatric populations. The quality of these scientific conversations directly affects both commercial performance and the organization’s credibility in the pediatric research community. For context on integrated medical and commercial operations, see medical affairs ops.
Conclusion
Pharma CEO business operations for pediatric drug development require integrating regulatory strategy, clinical science, formulation development, safety management, and commercial execution into a coherent operational program. The ethical responsibility of developing drugs for children demands exceptional organizational discipline, from early-phase protocol design through post-marketing safety surveillance.
The commercial incentives are real. The regulatory requirements are complex. And the mission, ensuring that children have access to medicines developed specifically for their biology and developmental stage, provides the moral foundation that should drive every operational decision. CEOs who build the capabilities to develop and commercialize pediatric products responsibly will find both commercial success and lasting institutional credibility in this critical therapeutic space.
Related Reading
For further context, explore Pharma CEO Business Operations Checklist and Allergy Portfolio Pharma CEO Business Operations: Strategic Execution Guide.